Education
About Us
Working with TipRanks
Follow Us
Organogenesis Holdings (ORGO)
:ORGO
ORGO Stock Chart & Stats
$4.08
-$0.06(-1.89%)
At close: 4:00 PM EST
$4.08
-$0.06(-1.89%)
Day’s Range― - ―
52-Week Range$2.61 - $6.71
Previous CloseN/A
Volume97.61K
Average Volume (3M)780.18K
Market Cap
$503.63M
Enterprise ValueN/A
Total Cash (Recent Filing)$63.74M
Total Debt (Recent Filing)$40.81M
Price to Earnings (P/E)―
Beta1.65
Next Earnings
Feb 26, 2026EPS Estimate
0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.12
Shares Outstanding126,857,710
10 Day Avg. Volume1,010,008
30 Day Avg. Volume780,182
Financial Highlights & Ratios
PEG Ratio-5.91
Price to Book (P/B)1.09
Price to Sales (P/S)0.87
P/FCF Ratio100.90
Enterprise Value/Market Cap0.00
Enterprise Value/Revenue0.00
Enterprise Value/Gross Profit0.00
Enterprise Value/Ebitda0.00
Forecast
1Y Price Target
$8.00Price Target Upside96.08% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Analyst RecommendationDespite the second trial's results, the analyst's recommendation for ORGO remains a Buy.
Future ProjectionsThe FY26 CMS proposal for skin substitutes is expected to benefit ORGO based on current product pricing.
Industry SupportLarger industry players are publicly supportive of the proposed changes to reimbursement for Skin Substitutes.
Bears Say
Clinical TrialsThe second Phase 3 trial did not achieve statistical significance for its primary endpoint, as the control group had better-than-expected improvements in pain.
Financial PerformanceRevenue of $101.0M missed estimates due to LCD dynamics and changes to CMS' proposals impacting results.
Pricing StrategyThe price for Affinity was set at $204.96 per sq. cm, down ~12.8% from the previous quarter and ~22.2% from the previous year.
Organogenesis Holdings News
ORGO FAQ
What was Organogenesis Holdings’s price range in the past 12 months?
Organogenesis Holdings lowest stock price was $2.61 and its highest was $6.71 in the past 12 months.
What is Organogenesis Holdings’s market cap?
Organogenesis Holdings’s market cap is $503.63M.
When is Organogenesis Holdings’s upcoming earnings report date?
Organogenesis Holdings’s upcoming earnings report date is Feb 26, 2026 which is in 110 days.
How were Organogenesis Holdings’s earnings last quarter?
Organogenesis Holdings released its earnings results on Nov 06, 2025. The company reported $0.123 earnings per share for the quarter, beating the consensus estimate of $0.065 by $0.058.
Is Organogenesis Holdings overvalued?
According to Wall Street analysts Organogenesis Holdings’s price is currently Undervalued.
Does Organogenesis Holdings pay dividends?
Organogenesis Holdings does not currently pay dividends.
What is Organogenesis Holdings’s EPS estimate?
Organogenesis Holdings’s EPS estimate is 0.22.
How many shares outstanding does Organogenesis Holdings have?
Organogenesis Holdings has 126,857,710 shares outstanding.
What happened to Organogenesis Holdings’s price movement after its last earnings report?
Organogenesis Holdings reported an EPS of $0.123 in its last earnings report, beating expectations of $0.065. Following the earnings report the stock price went up 44.73%.
Which hedge fund is a major shareholder of Organogenesis Holdings?
Currently, no hedge funds are holding shares in ORGO
Organogenesis Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$8.00 (96.08% Upside)
$8.00 (96.08% Upside)
Blogger Sentiment
Bullish
ORGO Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 1.8M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▲ 1.7%
Last 30 Days ▼ 2.8%
Last 30 Days ▼ 2.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
21.18%
12-Months-Change
Fundamentals
Return on Equity
-2.64%
Trailing 12-Months
Asset Growth
4.05%
Trailing 12-Months
Company Description
Organogenesis Holdings
Organogenesis Holdings Inc. is a leader in regenerative medicine, specializing in the development and commercialization of innovative advanced wound care and surgical biologics. The company operates primarily in the healthcare sector, focusing on products that utilize human cellular and tissue-based therapies. Its core offerings include dermal regeneration matrices, skin substitutes, and other advanced wound care solutions aimed at improving patient outcomes in chronic and complex wounds.
ORGO Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a strong performance in terms of revenue growth, exceeding guidance, and positive developments with CMS policy changes. However, there were notable challenges with the ReNu Phase III trial results, delays in LCD coverage submission, a slight decrease in gross profit margin, and a significant decrease in cash position.View all ORGO earnings summariesORGO Stock 12 Month Forecast
Average Price Target
$8.00
▲(96.08% Upside)
Technical Analysis
Ownership Overview
Currently, No data available
---